(DOC) Healthpeak Properties - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US42250P1030
Stock: Outpatient, Lab, CCRC
Total Rating 29
Risk 30
Buy Signal -0.06
| Risk 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Relative Tail Risk | -1.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -17.39 |
| Character TTM | |
|---|---|
| Beta | 0.348 |
| Beta Downside | 0.457 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.10% |
| CAGR/Max DD | 0.08 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 169.8
Description: DOC Healthpeak Properties February 28, 2026
Healthpeak Properties, Inc. (NYSE: DOC) is an S&P 500 REIT that acquires, operates, and develops high-quality U.S. healthcare real estate across three core segments: outpatient medical facilities, laboratory buildings, and continuing-care retirement communities (CCRCs). Organized as an umbrella partnership, the company holds the majority of its assets through its operating subsidiary, Healthpeak OP, and manages a portfolio of 703 properties-including 530 outpatient, 139 lab, and 15 CCRC sites-distributed nationwide from its Denver headquarters.
Recent performance highlights show FY 2024 funds-from-operations (FFO) of $1.25 per share, a 7% year-over-year increase driven by strong lease-up activity in the outpatient segment and rising rent escalations. Occupancy remains robust at 96%, while the dividend yield sits near 5.2%, reflecting the REIT’s commitment to cash-flow stability. Sector-wide, the aging U.S. population and a shift toward outpatient care are expanding demand for Healthpeak’s asset classes, with Medicare spending projected to grow 4% annually through 2027.
For a deeper dive into how Healthpeak’s fundamentals align with broader healthcare-real-estate trends, consider exploring its profile on ValueRay.
Headlines to watch out for
- Demand for medical office and lab space drives rental income
- Interest rate fluctuations impact financing costs and property valuations
- Healthcare policy changes affect tenant stability and occupancy rates
- Senior housing occupancy rates influence CCRC segment performance
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 71.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.40 > 1.0 |
| NWC/Revenue: 3.12% < 20% (prev 4.10%; Δ -0.98% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.26b > Net Income 71.3m |
| Net Debt (9.90b) to EBITDA (1.60b): 6.18 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (696.0m) vs 12m ago -0.51% < -2% |
| Gross Margin: 22.48% > 18% (prev 0.60%; Δ 2.19k% > 0.5%) |
| Asset Turnover: 14.02% > 50% (prev 13.54%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 1.78 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 305.2m) |
Altman Z'' -1.20
| A: 0.00 (Total Current Assets 1.07b - Total Current Liabilities 985.3m) / Total Assets 20.34b |
| B: -0.29 (Retained Earnings -5.95b / Total Assets 20.34b) |
| C: 0.03 (EBIT TTM 544.1m / Avg Total Assets 20.14b) |
| D: -0.44 (Book Value of Equity -5.27b / Total Liabilities 12.03b) |
| Altman-Z'' Score: -1.20 = CCC |
Beneish M -1.68
| DSRI: 0.82 (Receivables 684.3m/794.0m, Revenue 2.82b/2.70b) |
| GMI: 2.68 (GM 22.48% / 60.20%) |
| AQI: 1.00 (AQ_t 0.93 / AQ_t-1 0.93) |
| SGI: 1.05 (Revenue 2.82b / 2.70b) |
| TATA: -0.06 (NI 71.3m - CFO 1.26b) / TA 20.34b) |
| Beneish M-Score: -1.68 (Cap -4..+1) = CCC |
What is the price of DOC shares?
As of March 18, 2026, the stock is trading at USD 17.65 with a total of 9,825,323 shares traded.
Over the past week, the price has changed by +2.03%, over one month by +3.10%, over three months by +10.26% and over the past year by -7.73%.
Over the past week, the price has changed by +2.03%, over one month by +3.10%, over three months by +10.26% and over the past year by -7.73%.
Is DOC a buy, sell or hold?
Healthpeak Properties has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy DOC.
- StrongBuy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.9 | 12.6% |
| Analysts Target Price | 19.9 | 12.6% |
DOC Fundamental Data Overview March 15, 2026
P/E Trailing = 169.8
P/E Forward = 113.6364
P/S = 4.1813
P/B = 1.5736
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 8.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortLongTermDebt, last quarter)
Debt = 10.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.90b USD (from netDebt column, last quarter)
Enterprise Value = 21.77b USD (11.80b + Debt 10.44b - CCE 467.5m)
Interest Coverage Ratio = 1.78 (Ebit TTM 544.1m / Interest Expense TTM 305.2m)
EV/FCF = 18.57x (Enterprise Value 21.77b / FCF TTM 1.17b)
FCF Yield = 5.39% (FCF TTM 1.17b / Enterprise Value 21.77b)
FCF Margin = 41.55% (FCF TTM 1.17b / Revenue TTM 2.82b)
Net Margin = 2.53% (Net Income TTM 71.3m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = -87.20% (prev 58.64%)
Tobins Q-Ratio = 1.07 (Enterprise Value 21.77b / Total Assets 20.34b)
Interest Expense / Debt = 0.77% (Interest Expense 80.6m / Debt 10.44b)
Taxrate = 4.72% (6.03m / 127.8m)
NOPAT = 518.5m (EBIT 544.1m * (1 - 4.72%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.39 (Debt 10.44b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 6.18 (Net Debt 9.90b / EBITDA 1.60b)
Debt / FCF = 8.44 (Net Debt 9.90b / FCF TTM 1.17b)
Total Stockholder Equity = 7.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 71.3m / Total Assets 20.34b)
RoE = 0.91% (Net Income TTM 71.3m / Total Stockholder Equity 7.80b)
RoCE = 3.28% (EBIT 544.1m / Capital Employed (Equity 7.80b + L.T.Debt 8.77b))
RoIC = 3.04% (NOPAT 518.5m / Invested Capital 17.03b)
WACC = 4.17% (E(11.80b)/V(22.24b) * Re(7.20%) + D(10.44b)/V(22.24b) * Rd(0.77%) * (1-Tc(0.05)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 12.80%
[DCF] Terminal Value 87.31% ; FCFF base≈1.13b ; Y1≈1.26b ; Y5≈1.64b
[DCF] Fair Price = 55.35 (EV 48.37b - Net Debt 9.90b = Equity 38.47b / Shares 695.0m; r=5.90% [WACC]; 5y FCF grow 12.72% → 2.90% )
EPS Correlation: -33.73 | EPS CAGR: 13.23% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 10.28% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.05 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=0.19 | Chg7d=-0.060 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+387.2% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=0.20 | Chg7d=-0.055 | Chg30d=-0.055 | Revisions Net=-1 | Growth EPS=+5.3% | Growth Revenue=+3.7%
[Growth] Implied Growth Rate = 7.4% (Discount Rate 7.9% - Earnings Yield 0.6%)
[Growth] Growth Spread = -5.4% (Analyst 1.9% - Implied 7.4%)
P/E Forward = 113.6364
P/S = 4.1813
P/B = 1.5736
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 8.77b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortLongTermDebt, last quarter)
Debt = 10.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.90b USD (from netDebt column, last quarter)
Enterprise Value = 21.77b USD (11.80b + Debt 10.44b - CCE 467.5m)
Interest Coverage Ratio = 1.78 (Ebit TTM 544.1m / Interest Expense TTM 305.2m)
EV/FCF = 18.57x (Enterprise Value 21.77b / FCF TTM 1.17b)
FCF Yield = 5.39% (FCF TTM 1.17b / Enterprise Value 21.77b)
FCF Margin = 41.55% (FCF TTM 1.17b / Revenue TTM 2.82b)
Net Margin = 2.53% (Net Income TTM 71.3m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = -87.20% (prev 58.64%)
Tobins Q-Ratio = 1.07 (Enterprise Value 21.77b / Total Assets 20.34b)
Interest Expense / Debt = 0.77% (Interest Expense 80.6m / Debt 10.44b)
Taxrate = 4.72% (6.03m / 127.8m)
NOPAT = 518.5m (EBIT 544.1m * (1 - 4.72%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.39 (Debt 10.44b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 6.18 (Net Debt 9.90b / EBITDA 1.60b)
Debt / FCF = 8.44 (Net Debt 9.90b / FCF TTM 1.17b)
Total Stockholder Equity = 7.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 71.3m / Total Assets 20.34b)
RoE = 0.91% (Net Income TTM 71.3m / Total Stockholder Equity 7.80b)
RoCE = 3.28% (EBIT 544.1m / Capital Employed (Equity 7.80b + L.T.Debt 8.77b))
RoIC = 3.04% (NOPAT 518.5m / Invested Capital 17.03b)
WACC = 4.17% (E(11.80b)/V(22.24b) * Re(7.20%) + D(10.44b)/V(22.24b) * Rd(0.77%) * (1-Tc(0.05)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 12.80%
[DCF] Terminal Value 87.31% ; FCFF base≈1.13b ; Y1≈1.26b ; Y5≈1.64b
[DCF] Fair Price = 55.35 (EV 48.37b - Net Debt 9.90b = Equity 38.47b / Shares 695.0m; r=5.90% [WACC]; 5y FCF grow 12.72% → 2.90% )
EPS Correlation: -33.73 | EPS CAGR: 13.23% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 10.28% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.05 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=0.19 | Chg7d=-0.060 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+387.2% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=0.20 | Chg7d=-0.055 | Chg30d=-0.055 | Revisions Net=-1 | Growth EPS=+5.3% | Growth Revenue=+3.7%
[Growth] Implied Growth Rate = 7.4% (Discount Rate 7.9% - Earnings Yield 0.6%)
[Growth] Growth Spread = -5.4% (Analyst 1.9% - Implied 7.4%)